Live
- People will not forgive Congress for repeatedly insulting Constitution: Kiren Rijiju
- Aid group resumes activities at famine-hit camp in Sudan
- Kishan Reddy Vows to End BRS and Congress Influence in Telangana, Criticizes CM's Governance
- Punjab bypolls: Bittu twisting words for political gains, says Congress nominee
- Punjab CM to administer oath to over 10,000 sarpanches on Friday
- BJP Core Committee Plans Protests Against State Government’s Failures
- Mulugu Collector Divakar's Facebook Hacked Again, Cyber Criminals Send Fraudulent Messages Asking for Money
- The Role of Genetics in Obesity: Can Metabolic Bariatric Surgery Help?
- Deputy CM Bhatti Vikramarka's Visit to Khammam District: Lays Foundation for Road Works Worth Rs. 8.9 Crore
- ED Files Charge Sheet in Agrigold Case, Attaches Assets Worth Over ₹4,100 Crores
Strides Pharma gets USFDA nod to market HIV drugHIV drug
Strides Pharma Science on Wednesday said its subsidiary has received approval from the US health regulator to market a generic version of Gilead Sciences' Atripla tablets which are indicated to help control HIV infection.
New Delhi: Strides Pharma Science on Wednesday said its subsidiary has received approval from the US health regulator to market a generic version of Gilead Sciences' Atripla tablets which are indicated to help control HIV infection.
Singapore-based Strides Pharma Global, a stepdown wholly-owned subsidiary of the company, has received approval for Efavirenz (600mg), Emtricitabine (200mg), Tenofovir Disproxil Fumurate (300mg), (EET) tablets from the US Food & Drug Administration (USFDA), the drug firm said in a statement. The company's product is bioequivalent and therapeutically equivalent to Atripla Tablets of Gilead Sciences LLC, it added. As per per IQVIA, Efavirenz, Emtricitabine and Tenofovir Disoproxil Fumurate tablet (EET) has a market opportunity of USD 7.5 million in the US. Shares of Strides Pharma Science ended 2.51 per cent up at Rs 508.20 apiece on the BSE on Wednesday
